Azurity Pharmaceuticals

Specialty/reformulated branded generics (BiDil)

Privately held: no public share price · United States

Assets

(10 total)
10Total Assets
10Approved
0Phase 3 / Filed
0Phase 1–2 / Early
9Diseases
Quick filter:
Showing 10 of 10 assets
Target & Modality
Aclidinium bromide(Tudorza Pressair)
Approved
Muscarinic acetylcholine receptor (M3)Small molecule
Chronic Obstructive Pulmonary Disease
Approved
Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptorSmall molecule
Chronic Obstructive Pulmonary Disease
Approved
Glucocorticoid receptorSmall molecule
Asthma
Ferumoxytol(Feraheme)
Approved
IV iron replacement therapyOther
Chronic Kidney DiseaseIron Deficiency Anemia
Approved
Hydralazine/isosorbide dinitrate (fixed combination)Small molecule
Heart Failure
Approved
Opioid receptor / dopamine (combination) · Dopamine/norepinephrine transporterSmall molecule
Obesity
Approved
5-HT1B/1D receptorSmall molecule
Migraine
Approved
5-HT1B/1D receptor · Nonsteroidal Anti-inflammatory DrugSmall molecule
Migraine
Approved
Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydraseSmall molecule
EpilepsyMigraineLennox-Gastaut Syndrome
Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures
Approved
Voltage-gated sodium and T-type calcium channelsSmall molecule
Epilepsy
Focal Onset Seizures

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 October 2025ApprovalFerumoxytolFDA approves Ferabright (ferumoxytol injection) for brain MRI
US, FDA · Source ↗

Financial reports

No financial reports recorded.